

Glenmark Pharmaceuticals Europe Ltd  
IFRS Reporting Pack


Statement of Financial Position	Sch	As at	
		31-03-2023	31-03-2022
		Local Currency	Local Currency
		IFRS-GBP	IFRS-GBP
<b>ASSETS</b>			
<i>Current assets</i>			
Cash and cash equivalents	A	16,696,437	11,428,885
Restricted cash	B	15,000	15,000
Trade receivables	C	40,452,356	25,991,642
Inventories	D	15,522,689	8,666,436
Other short-term financial assets	E	6,962,153	5,002,878
Other current assets	F	369,935	446,786
Current tax assets	J	-	-
<b>Total current assets</b>		<b>80,018,570</b>	<b>51,551,627</b>
<i>Non current assets</i>			
Property, plant and equipment	G	127,612	128,106
Other Intangible Assets	H	8,001,231	9,990,382
Right of use assets	I	2,359,896	2,807,442
Non-current tax assets			
Deferred tax assets	K	122,326	120,885
Restricted cash	D	-	-
Long term financial assets	L	555,415	555,415
<b>Total non - current assets</b>		<b>11,166,480</b>	<b>13,602,230</b>
<b>Total assets</b>		<b>91,185,050</b>	<b>65,153,857</b>
<b>EQUITY AND LIABILITIES</b>			
<i>Current liabilities</i>			
Trade payables	M	24,218,251	2,689,850
Current tax liabilities	N	326,501	103,218
Lease liability short term	O	551,011	509,469
Loan from related parties	P	27,174,365	36,888,992
Other liabilities	Q	4,762,993	1,006,207
Short-term financial liabilities	R	12,813,049	4,148,945
Provisions	S	-	-
<b>Total current liabilities</b>		<b>69,846,170</b>	<b>45,346,681</b>
<i>Non-current liabilities</i>			
Long-term borrowings	T	-	-
Other liabilities	U	-	-
Lease liability long term	V	2,234,410	2,745,939
Deferred tax liabilities	K	-	-
<b>Total non-current liabilities</b>		<b>2,234,410</b>	<b>2,745,939</b>
<b>Total liabilities</b>		<b>72,080,580</b>	<b>48,092,620</b>
<i>Stockholders' equity</i>			
Share capital	W	6,285,121	6,285,121
Share Premium		-	-
Statutory reserve		-	-
Currency translation reserve		-	-
Retained earnings		12,819,349	10,776,116
Non Controlling Interest		-	-
<b>Total stockholders' equity</b>		<b>19,104,470</b>	<b>17,061,237</b>
<b>Total equity and liabilities</b>		<b>91,185,050</b>	<b>65,153,857</b>





Glenmark Pharmaceuticals Europe Ltd  
IFRS Reporting Pack

Statement of Comprehensive Income	Sch	IFRS-GBP	
		Local Currency	Local Currency
		IFRS	IFRS
<b>INCOME</b>			
Operating Revenue	X	75,516,353	51,524,576
Other income	Y	-	211,437
<b>Total</b>		<b>75,516,353</b>	<b>51,736,013</b>
Materials consumed	Z	-	-
Changes in Inventories of FG and WIP		(6,856,253)	1,835,066
Purchase of Traded Goods		53,187,620	27,071,433
Employee benefit expenses	AA	13,092,793	11,924,383
Other expenses	AB	10,940,863	7,713,986
Depreciation, amortisation and impairment of non-financial assets	AC	842,228	939,230
Depreciation of right-of-use assets		495,429	487,542
<b>Total</b>		<b>71,702,680</b>	<b>49,971,640</b>
<b>Operating profit</b>		<b>3,813,673</b>	<b>1,764,373</b>
Interest expense, lease liabilities	AE	152,733	175,388
Finance costs	AE	1,269,408	900,836
Finance income	AD	19,257	3,832
<b>Profit/(Loss) before tax</b>		<b>2,410,789</b>	<b>691,981</b>
Current tax expenses	AF	368,968	91,185
Deferred tax expenses	AF	(1,412)	(17,159)
Total Tax expenses		367,556	74,026
<b>Profit/(Loss) after tax from continuing operations</b>		<b>2,043,233</b>	<b>617,955</b>





Glenmark Phramceuticals Europe Ltd  
IFRS Reporting Pack

A Cash and cash equivalents

Cash and cash equivalents include the components as follows:

Particulars	IFRS-GBP	
	Local Currency	Local Currency
	IFRS	IFRS
Cash on hand	25	164
Cash in current accounts	16,696,412	11,428,721
Cash deposits short term	-	-
<b>Total</b>	<b>16,696,437</b>	<b>11,428,885</b>

B Restricted Cash

Restricted cash comprise the following;

Particulars	IFRS-GBP		31-03-2022	
	Local Currency		Local Currency	
	IFRS		IFRS	
<b>Current</b>				
Cash Collateral				
Deposits		15,000		15,000
<b>Total</b>		<b>15,000</b>		<b>15,000</b>
<b>Non-current</b>				
Time deposits				-
<b>Total</b>				

C Trade receivables [other receivables can be merged here, if material]


The carrying amount of trade receivables are analysed as follows:

Particulars	IFRS-GBP		31-03-2022	
	Local Currency		Local Currency	
	IFRS		IFRS	
Other receivable				
Trade Debtor		18,635,048		5,142,975
Inter co. Debtors		22,427,303		20,848,667
Provision for doubtful debts		(609,995)		-
<b>Net trade receivables</b>		<b>40,452,356</b>		<b>25,991,642</b>

D Inventories

Inventories recognised in the statement of financial position can be analysed as follows:

Particulars	IFRS-GBP		31-03-2022	
	Local Currency		Local Currency	
	IFRS		IFRS	
Raw Materials		-		-
Inven - FG		7,103,887		5,041,901
Inven - FG - In Lice		7,643,743		4,143,200





Inven - FG - Traded	49,465	4,015
Inven - FG - In Tran	1,493,783	328,719
Inven - FG - IL sample	1,389,833	36,893
Inven-FG InHouse-Sam	15,734	21,305
Provn Inventory Res	(2,173,756)	(909,597)
<b>Total</b>	<b>15,522,689</b>	<b>8,666,436</b>

**E Short term financial assets**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
ST IC loan	959,281	
Deposit paid	2,872	2,878
Short term deposits-advance against supplies	6,000,000	5,000,000
<b>Total</b>	<b>6,962,153</b>	<b>5,002,878</b>

**F Other current assets**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Prepayment and other advances	369,935	446,786
<b>Total</b>	<b>369,935</b>	<b>446,786</b>

**G Property, Plant and Equipment**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Gross Block PPE	1,125,870	1,367,868
Accumulated depreciation PPE	998,258	1,239,762
Net Block	127,612	128,106
Capital work in progress	-	-
<b>Total</b>	<b>127,612</b>	<b>128,105</b>

**H Other Intangible assets**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Gross Block Intangible	14,825,781	16,737,871
Accumulated depreciation Intangible	6,824,550	6,747,489
Net Block	8,001,231	9,990,382
Capital work in progress	-	-
<b>Total</b>	<b>8,001,231</b>	<b>9,990,382</b>





1 Right of use assets

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Right of use assets	3,857,299	3,809,411
Right of use Accumulated depreciation	1,497,403	1,001,969
Net Block	2,359,896	2,807,442
	2,359,896	2,807,442





**J Current tax assets**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Advance Tax		
Total	-	-

**K Deferred tax assets**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
DTA	122,326	120,885
Total	122,326	120,885

**L Long term financial assets**

Long term financial assets comprise of the following:


Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
<b>Held-to-maturity financial assets</b>		
Security deposits assets	-	-
Bonds	-	-
<b>Investments in Subsidiaries</b>		
- In Glen. Argentina by GPL India	555,415	555,415
<b>Total</b>	<b>555,415</b>	<b>555,415</b>

**M Trade payables**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Sundry creditors	960,000	2,446,196
Inter co. creditors	23,258,251	243,654
Acceptances	-	-
<b>Total</b>	<b>24,218,251</b>	<b>2,689,850</b>

**N Current tax liabilities**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Provision for Tax	326,501	103,218
<b>Total</b>	<b>326,501</b>	<b>103,218</b>





O Lease liability short term

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Lease liability- ST	551,011	509,469
Total	551,011	509,469

P Loan from related parties

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Current portion of long-term borrowings	-	-
Interco Loan	27,174,365	36,888,992
Total	27,174,365	36,888,992

Q Other current liabilities

Other current liabilities are summarized as follows:

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Advances received from customer	-	-
Income received in advance	-	-
Statutory dues	4,762,993	1,006,207
Input taxes payable	-	-
Total	4,762,993	1,006,207


R Short-term financial liabilities

Other current liabilities are summarized as follows:

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Employee dues	-	(0)
Accrued Expenses	12,813,049	4,148,945
Interest accrued but not due	-	-
Total	12,813,049	4,148,945


S Provisions

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Provision for compensated absences	-	-





Provision for gratuity benefit plan	-	-
Provision for Employee benefits	-	-
<b>Total</b>	-	-





**T Long Term Borrowing**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Notes payable	-	-
Term loan from banks	-	-
Inter company loan	-	-
<b>Total</b>	-	-

**U Other liabilities (Non-Current)**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
<b>Total</b>	-	-

**V Lease liability long term**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Lease liabilities LT	2,234,410	2,745,939
Others	-	-
<b>Total</b>	2,234,410	2,745,939


**W Equity**

Particulars	IFRS-GBP	31-03-2022
	Local Currency	Local Currency
	IFRS	IFRS
Equity attributable to owners of the parent:		
Share capital	6,285,121	6,285,121
Add- Share issued during the year	6,285,121	6,285,121
Share application money	-	-
Share Premium	-	-
<u>Statutory Reserve</u>	-	-
Capital redemption reserve	-	-
Capital reserve	-	-
Currency translation reserve	-	-
Reserve & Surplus	-	-
<u>Retained earnings</u>	10,776,116	10,158,161
Profit & Loss balance	2,043,233	617,955
Current period profit		
Exchange Fluctuation Reserve		
Transfer to General reserve		





General reserve		
Total	12,819,349	10,776,116
Total Equity	19,104,470	17,061,237





Glenmark Pharmaceuticals Europe Ltd  
IFRS Reporting Pack  
Schedule - X

X Income from operations

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
Sale goods & out licensing	67,769,926	45,668,071
other operating revenue	-	-
Income from services	7,746,427	5,856,505
<b>Total</b>	<b>75,516,353</b>	<b>51,524,576</b>

Schedule - Y

Y Other income

Other income is summarised as follows:

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
Dividend on short term investments	-	-
Profit on sale of short term investments	-	-
Profit on sale of fixed assets	-	-
Exchange Gain & Loss	(0)	211,437
Freight Recovery	-	-
Misc income	-	-
<b>Total</b>	<b>(0)</b>	<b>211,437</b>

Schedule - Z


Z Material Consumed

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
Consumption of Raw Material		
Consumption of Packing Material		
<b>Total</b>	<b>-</b>	<b>-</b>

Schedule - Z

Z Changes in Inventory of FG and WIP

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
(Increase)/Decrease in Stock of Finished goods/WIP	(6,856,253)	1,835,066
<b>Total</b>	<b>(6,856,253)</b>	<b>1,835,066</b>





## Schedule - Z

## Z Purchase of Traded Goods

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
Purchase of Traded Goods		
Inven - FG - Traded	53,187,620	27,071,433
<b>Total</b>	<b>53,187,620</b>	<b>27,071,433</b>

## Schedule - AA


## AA Employee benefit expenses

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
Salaries and bonus	10,809,106	9,719,176
Medical Allowance	-	-
N Ins-Employer Contr	1,364,832	1,193,029
Relocation Expenses	7,126	25,765
Res. Accom-Employee	0	0
Staff welfare expenses	178,077	149,564
Car Lease-Employees	6,953	13,795
Car Maint-Employees	-	-
Office Retainers	-	-
Recruitment Expenses	218,277	277,379
Retirement benefits	499,467	520,652
Training Expenses	8,955	25,025
<b>Total</b>	<b>13,092,793</b>	<b>11,924,383</b>

## Schedule - AB

## AB Other Expenses

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
Rent	-	-
Rates & Taxes	145,879	162,606
Sales Promotion	1,778,035	1,826,138
Car Lease	-	-
Office Mainten. Exp	85,968	60,524
Car Maintenance	42	117
Travelling expenses	779,390	324,695
Auditors remuneration	-	-
Freight Outward-Dom	1,238,830	1,016,039
Freight Outward-Export	-	-
Comp. Hardware Maint	7,454	16,059
Connectivity charges	9,630	8,375
Insurance Charges	63,142	16,944
Repairs for Others	9,591	574
Other expenses	66,198	42,382
Translate & Interpre	-	4,412
Telephone expenses	65,660	68,480
Other Manufacturing Expenses	-	-
Lease of low value	-	-
Short term lease	4,641	(0)





Product Registration Exp	3,062	2,465
Legal Expenses	71,082	93,238
Professional Exp.	1,780,567	1,308,328
Car Rent & Fuel	-	-
General Expenses	23,026	29,560
Test & Trial & Development exp	1,185,131	1,465,430
Service Charges	141,802	169,976
Inspection/Testing	18,189	-
Drug Development Reg	-	-
Audit Fees-Statutory	29,645	39,300
Audit-Out of Pocket	60	1,260
Conveyance	-	-
Conference expenses	49,581	10,592
Printing and stationery	4,275	10,818
Stationery	5,592	7,749
Subscription & Memb	575,467	392,009
Postage, stamps, telegrams & courier charges	29,339	30,951
Electricity Charges	55,397	34,461
Water Charges	-	-
R&D Innovator Samp	-	3,469
Books & Periodicals	76,007	81
Bad Debt Provn	609,995	-
Meeting Expenses	13,894	11,416
Renewal & Mainte Fee	-	(1)
Submission Fee	-	-
Variation Fee	44,108	50,991
Annual Fees	447,199	428,708
Regula Consultants	15,412	59,577
Write off FA	1,009,065	-
Computer Consumables	4,719	1,176
Loss on Forex	478,125	-
Bank Charges	7,626	6,989
Payroll Processing	8,038	8,097
Non Capitalize Exp	-	-
Pre Cap - AUC	-	-
Pre Cap - Non AUC	-	-
<b>Total</b>	<b>10,940,863</b>	<b>7,713,986</b>





Schedule - AC

AC Depreciation, amortisation and impairment of non-financial assets & right of use assets

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
Depreciation, amortisation and impairment of non-financial assets	-	-
Depreciation of right-of-use assets	495,429	487,542
Depreciation on Tangible assets	61,731	112,993
Depreciation on Intangible assets	780,497	826,237
<b>Total</b>	<b>1,337,657</b>	<b>1,426,772</b>

Schedule - AD

AD Finance income

Finance income is analysed as follows:

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
Interest income on interco	19,257	-
Interest Income on Fixed Deposits	-	-
Other Interest income	-	-
Int Income - Other	-	3,832
<b>Total</b>	<b>19,257</b>	<b>3,832</b>

Schedule - AE

AE Finance costs


Finance costs is analysed as follows:

Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
- Interest expense on short term borrowings		
Term loans		
Finance costs -others	-	-
Interest Expense - IC	1,125,020	858,649
Interest Expense - Others	144,388	42,187
Interest expense, lease liabilities	152,733	175,388
<b>Total</b>	<b>1,422,140</b>	<b>1,076,225</b>

Schedule - AF

AF Income tax (expense)/credit



Particulars	IFRS-GBP	3/31/2022
	Local Currency	Local Currency
	IFRS	IFRS
Current income tax	368,968	91,185
Deferred tax	(1,412)	(17,159)
Prior period income tax	-	-
<b>Total</b>	<b>367,556</b>	<b>74,025</b>






Glenmark Pharmaceuticals Europe Ltd  
IFRS Reporting Pack

Particulars	Local currency	Local currency
	31-Mar-23	31-Mar-22
<b>(A) CASH INFLOW / (OUTFLOW) FROM OPERATING ACTIVITIES</b>		
Profit before tax	2,410,789	691,980
Adjustments to reconcile profit before tax to net cash provided by operating activities:		
Depreciation and amortisation		
Depreciation of right-of-use assets	842,228	939,230
Employee share based compensation	495,429	487,542
Interest expense		
- Interest expense - Intercompany	1,125,020	858,649
- Interest expense - Other than Intercompany	144,388	42,188
Interest expense, lease liabilities	152,733	175,388
Interest income		
- Interest income - Intercompany	(19,257)	-
- Interest income - Other than Intercompany	-	(3,831)
Other finance cost - corporate guarantee	-	-
Dividend income	-	-
Write off of Intangibles and intangibles under development	1,009,065	-
(Profit)/Loss on sale of enterprise	-	-
(Profit)/Loss on sale of investments	-	-
Employee benefit obligation	-	-
Provision for bad and doubtful debts	609,995	-
Unrealised foreign exchange (gain)/loss***	1,118,577	(1,226,899)
<b>Operating profit before changes in operating assets and liabilities</b>	<b>7,888,967</b>	<b>1,964,247</b>
<b>Changes in operating assets and liabilities</b>		
- (Increase) / Decrease in trade receivables		
- (Increase) / Decrease in trade receivables - Intercompany	(1,654,256)	1,454,230
- (Increase) / Decrease in trade receivables - Other than Intercompany	(13,491,993)	3,001,108
- (Increase) / Decrease in other assets and short term fin Assets	-	-
- (Increase) / Decrease in other assets and short term fin Assets - Intercompany	(1,956,912)	8,000,000
- (Increase) / Decrease in other assets and short ther fin Assets- Other than Intercompany	76,856	(104,864)
-(Increase) / Decrease in inventories	(6,856,253)	1,835,066
- Increase / (Decrease) in trade payables		
- (Increase) / Decrease in trade payables - Intercompany	23,142,460	(11,842,500)
- (Increase) / Decrease in trade payables - Other than Intercompany	(1,488,681)	(915,712)
- Increase / (Decrease) in other liabilities and other financial liabilities		
- (Increase) / Decrease in other liabilities and other financial liabilities - Intercompany	-	-
- (Increase) / Decrease in other liabilities and other financial liabilities- Other than Intercompany	12,420,701	365,873
<b>Net changes in operating assets and liabilities</b>	<b>10,191,923</b>	<b>1,793,202</b>
- Income taxes paid	(145,684)	(0)
<b>Net cash from operating activities</b>	<b>17,935,206</b>	<b>3,757,448</b>
<b>(B) CASH INFLOW / (OUTFLOW) FROM INVESTING ACTIVITIES</b>		
Restricted Cash		
Interest received		
- Interest received - Intercompany	14,259	-
- Interest received - Other than Intercompany	-	3,831
Dividend received		
Payments for purchase of property, plant and equipment and intangible assets**	(122,942)	(3,231,662)
Proceeds from sale of property, plant and equipment	261,467	-
Investments in subsidiaries		
Sale of Investment in Subsidiary		
Long Term Financial Assets	1	-





Loans and advances to subsidiaries/enterprise		
Share application money paid	-	-
<b>Net cash used in investing activities</b>	<b>152,785</b>	<b>(3,227,831)</b>





<b>(C) CASH INFLOW / (OUTFLOW) FROM FINANCING ACTIVITIES</b>		
Proceeds from long term borrowings		
- Proceeds from long term borrowings - Intercompany		
- Proceeds from long term borrowings - Other than Intercompany	-	-
Repayments of long term borrowings		
- Repayments of long term borrowings - Intercompany		
- Repayments of long term borrowings - Other than Intercompany	-	-
Proceeds from short term borrowings		1
- Proceeds from short term borrowings - Other than Intercompany	-	-
Repayments of short term borrowings		
- Repayments of short term borrowings - Other than Intercompany	(11,594,326)	-
Proceeds/ (Repayment) of working capital facilities	-	-
Interest paid		
- Interest paid - Intercompany	(411,118)	(1,084,443)
- Interest paid - Other than Intercompany	(144,388)	(42,188)
Interest paid lease liabilities	(152,733)	(175,388)
Amortisation payments, lease instalments	(517,875)	(430,977)
other finance cost -corporate guarantee	-	-
Transaction with non-controlling interest		
Stock compensation expenses	-	-
Dividend paid (including tax on dividend)	-	-
<b>Net cash from financing activities</b>	<b>(12,820,438)</b>	<b>(1,732,996)</b>
Effect of exchange rate changes on cash		
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>5,267,552</b>	<b>(1,203,381)</b>
Cash and cash equivalents at the beginning of the year	11,428,885	12,632,266
Cash and cash equivalents acquired on Merger		
<b>Cash and cash equivalents at the end of the year</b>	<b>16,696,437</b>	<b>11,428,885</b>
As per Balance sheet	5,267,552	(1,203,381)

\*\* This amount includes the goodwill acquisition for 3019% on account of R & D Business purchase in the previous year 2021-2022.

\*\*\* The changes in assets and liabilities are without the impact of unrealised foreign exchange gain/(losses) which are already adjusted under the adjustments to reconcile profit before tax to net cash provided by operating activities.





Glenmark Pharmaceuticals Europe Ltd  
Other intangible assets

Particulars	Computer software	Intangibles under constr.	Trademark/Licenses/ Brands/ Product Knowhow	Licenses	Goodwill	Total
<b>Cost</b>						
Balance as at April 1, 2021	1,015,248	152,898	12,346,861	12,531,759	-	13,545,007
- Internally developed						
- Acquired through business combinations						
- Other acquisitions		190,985	75,109	266,094	3,014,701	3,280,795
- Disposals/ Transfers		(87,530)		(87,930)		(87,930)
- Transition adjustment						
Balance as at March 31, 2022	1,015,248	285,953	12,423,970	12,709,923	3,014,701	16,737,872
- Internally developed						
- Acquired through business combinations						
- Other acquisitions		61,230		61,230		61,230
- Disposals/ Transfers	(208)	(260,752)	(1,712,361)	(1,973,113)		(1,973,321)
- Transition adjustment						
Balance as at March 31, 2023	1,015,040	86,431	10,711,609	10,798,040	3,014,701	14,825,781
<b>Amortisation and impairment</b>						
Balance as at April 1, 2021	(448,876)	-	(5,472,376)	(5,472,376)	-	(5,921,252)
- Amortisation charge for the year	(194,590)		(631,647)	(631,647)		(826,237)
- Impairment						
- Amortisation charge for disposals/ transfers						
- Transition adjustment						
Balance as at March 31, 2022	(643,466)	-	(6,104,023)	(6,104,023)	-	(6,747,489)
- Amortisation charge for the year	(192,021)		(588,476)	(588,476)		(780,497)
- Impairment loss						
- Impairment	208.00		703,228	703,228		703,436
- Amortisation charge for disposals/ transfers						
- Transition adjustment						
Balance as at March 31, 2023	(835,279)	-	(5,989,271)	(5,989,271)	-	(6,824,550)


Particulars	Computer software	Intangibles under constr.	Trademark/Licenses/ Brands/ Product Knowhow	Licenses	Goodwill	Total
<b>Carrying value</b>						
At March 31, 2021	564,372	182,898	6,874,685	7,059,383	-	7,623,755
At March 31, 2022	369,782	285,953	6,319,947	6,605,000	3,014,701	9,990,383
At March 31, 2023	177,761	86,431	4,722,338	4,808,769	3,014,701	8,001,231





Tangible- GPEL IFRS Pack

Particulars	Local Currency										Total	
	Factory Building	Other Premises	Vehicles	Plant & Machinery	Furniture	Computers	Equipment & Aircondition	Office Equipment	Freehold Land	CWIP		
<b>Cost</b>												
Balance as at April 1, 2021	-	-	-	-	584,122	599,354	-	145,595	-	-	-	1,329,071
- Acquisitions	-	-	-	-	-	38,797	-	-	-	-	-	38,797
- Other acquisitions	-	-	-	-	-	-	-	-	-	-	-	-
- Disposals/Transfers	-	-	-	-	-	-	-	-	-	-	-	-
- Translation adjustment	-	-	-	-	-	-	-	-	-	-	-	-
<b>Balance as at March 31, 2022</b>	-	-	-	-	584,122	638,151	-	145,595	-	-	-	1,367,868
- Acquisitions through business combinations	-	-	-	-	-	53,264	-	8,448	-	-	-	61,712
- Other acquisitions	-	-	-	-	-	(300,140)	-	(3,570)	-	-	-	(903,710)
- Disposals/Transfers	-	-	-	-	-	-	-	-	-	-	-	-
- Translation adjustment	-	-	-	-	-	-	-	-	-	-	-	-
<b>Balance as at March 31, 2023</b>	-	-	-	-	584,122	391,275	-	150,473	-	-	-	1,125,870
<b>Accumulated Depreciation</b>												
Balance as at April 1, 2021	-	-	-	-	(557,201)	(452,960)	-	(116,608)	-	-	-	(1,126,769)
- Depreciation charge for the year	-	-	-	-	(25,205)	(65,318)	-	(24,470)	-	-	-	(112,993)
- Impairment loss recognized	-	-	-	-	-	-	-	-	-	-	-	-
- Disposals/Transfers	-	-	-	-	-	-	-	-	-	-	-	-
- Translation adjustment	-	-	-	-	-	-	-	-	-	-	-	-
<b>Balance as at March 31, 2022</b>	-	-	-	-	(582,406)	(516,278)	-	(141,078)	-	-	-	(1,239,762)
- Depreciation charge for the year	-	-	-	-	(1,259)	(54,563)	-	(5,929)	-	-	-	(61,731)
- Impairment loss recognized	-	-	-	-	-	-	-	-	-	-	-	-
- Disposals/Transfers	-	-	-	-	-	299,664	-	3,570	-	-	-	303,234
- Translation adjustment	-	-	-	-	-	-	-	-	-	-	-	-
<b>Balance as at March 31, 2023</b>	-	-	-	-	(583,644)	(271,177)	-	(143,437)	-	-	-	(998,259)
<b>Carrying value</b>												
At April 1, 2021	-	-	-	-	26,921	146,394	-	28,987	-	-	-	202,302
At March 31, 2022	-	-	-	-	1,716	121,872	-	4,517	-	-	-	128,106
At March 31, 2023	-	-	-	-	479	120,098	-	7,056	-	-	-	127,612





**Glenmark Pharmaceuticals Limited (Name of entity)**

Notes to the Financial Statements

**Lease Liabilities**

Particulars	31-03-2023	31-03-2022
	(Amt in LCY)	(Amt in LCY)
<b>Non-current</b>		
- Buildings	2,208,340	2,738,495
- Plant and Equipments		
- Furniture & Fixtures		
- Office Equipments		
- Vehicles	26,070	7,444
<b>Sub-total</b>	<b>2,234,410</b>	<b>2,745,939</b>
<b>Current</b>		
- Buildings	530,153	504,350
- Plant and Equipments		
- Furniture & Fixtures		
- Office Equipments		
- Vehicles	20,858	5,119
<b>Sub-total</b>	<b>551,011</b>	<b>509,469</b>
<b>Total</b>	<b>2,785,421</b>	<b>3,255,408</b>

Maturity analysis	31-03-2023	31-03-2022
	(Amt in LCY)	(Amt in LCY)
Not later than 1 year	551,011	509,469
Later than 1 year and not later than 5 years	2,234,410	2,296,421
Later than 5 years	(0)	449,518
	2,785,421	3,255,408





Glenmark Pharmaceuticals Europe Ltd  
Statement of Changes in Equity

	Share Capital	APIC/Share Premium	Available for-sale financial assets	Retain earnings	Reserves & Surplus	Revaluation reserve	Currency translation reserve	Total attributable to owners of parent	Total equity
Balance as at April 1, 2021	6,285,121			10,158,161					16,443,282
Dividends									
Issue of share capital									
Transactions with owners									
Profit for the period ended Mar22				617,955					617,955
<b>Other comprehensive income:</b>									
Cash flow hedging									
- current year gains (losses)									
- reclassification to profit or loss									
Available-for-sale financial assets									
- current year gains (losses)									
- reclassification to profit or loss									
Difference from method change 2012									
Exchange differences on translating foreign operations									
Share of other comprehensive income of equity accounted investments									
- reclassification to profit or loss									
Income tax relating to components of other comprehensive income									
<b>Total comprehensive income for the year</b>									
Balance as at 31-03-2022, 31-03-2022, 31-03-2022	6,285,121			10,776,116					17,061,237
Dividends									
Issue of share capital									
Transactions with owners									
Audit adjustment regarding the difference in the OB									
Profit for the period				2,043,233					2,043,233
<b>Other comprehensive income:</b>									
Cash flow hedging									
- current year gains (losses)									
- reclassification to profit or loss									
Available-for-sale financial assets									
- current year gains (losses)									
- reclassification to profit or loss									
Difference from method change									
Exchange differences on translating foreign operations									
Income tax relating to components of other comprehensive income									
<b>Total comprehensive income for the year</b>									
Balance as at March 31, 2023	6,285,121			12,819,349					19,104,470

